Validation experiment designed to validate causal mechanisms targeting FCGRT in IgG1-Fc humanized hFCGRT transgenic mice. Primary outcome: Serum half-life of administered humanized monoclonal antibodies
This experiment evaluated the pharmacokinetic behavior of administered humanized monoclonal antibodies in the newly created IgG1-Fc humanized mice compared to control conditions. The study demonstrated that endogenous chimeric IgG1 produced by the engineered mice significantly dampened the serum half-life of administered humanized mAbs in an hFCGRT-dependent manner. This competitive effect was designed to more accurately model the human physiological condition where endogenous human IgG competes with therapeutic antibodies for FcRn binding, providing a more translationally relevant preclinical model for human IgG-based biologics development.
Administration of humanized mAbs to IgG1-Fc humanized mice followed by pharmacokinetic analysis and comparison to control conditions
Reduced serum half-life of administered humanized mAbs due to competition with endogenous chimeric IgG1
Significant dampening of humanized mAb serum half-life in an hFCGRT-dependent manner
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.